Mammoth Biosciences

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

  • 2023 Best Places to Work
WHO WE ARE

We are a team of scientists, entrepreneurs, and dreamers who are building the platform for CRISPR applications of the future.

· Mission 1st

We are developing technologies and products that we are passionate about and that can have a mammoth impact.

· Innovation

Discovery is in our RNA. We stay at the forefront of both patient impact and scientific advancement by combining our creativity with experience to take intelligent risks.

· Accountability

We have the privilege to work with transformative technologies and amazing people, and we have the responsibility to make sure we are having the most positive impact possible both on the world and in our team.

· Execute with Urgency

Patients are counting on us and we make it happen. We focus on the most important and high impact opportunities and do work that matters.

· Inclusion & Diversity

Our Mammoth strength comes from the diversity of nature and of our people.

Full Benefits

We cover 100% of employee benefits for medical, dental, vision and life insurance.

401(k)

Our 401(k) plan includes company matching of employee contributions.

Unlimited Vacation

We have an unlimited vacation policy that allows you to get the rest and relaxation you need to refresh.

Transportation Subsidy

We provide a public transportation commuter subsidy.

Onsite Food and Amenities

We offer several free amenities including snacks and drinks, as well as lunch and dinner.

Happy Hours

We encourage our team to unwind and get to know each other through company happy hours.

NEWS
Ultracompact CRISPR systems, which are in some cases one-third the size of Cas9, are being designed to be more specific and enable in vivo gene editing in difficult to reach tissues.
Regeneron will use Mammoth Biosciences’ tiny Cas enzymes to deliver in vivo CRISPR-based gene editing therapies to tissues and cell types beyond the liver, the companies announced Thursday.
Today, scientist-founders are likely to remain in charge, shepherding the companies they founded to the next iteration. BioSpace spoke with one such founder, Mammoth Biosciences’ Trevor Martin.
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
JOBS
IN THE PRESS